Meny
Meny
Our mission is to enable Scandinavian scientists and entrepreneurs to build the companies that solve the world’s most important problems.
With leading academic life sciences and medical institutions in the region, Cardeon creates fundamental medical technology, diagnostic tools and biotech companies built on science.
Through Cardeon’s unique venture platform, we put scientists together with experienced entrepreneurs and capital, to turn local innovations into global impact, Scandinavian concepts into international companies.
Channeling capital to Scandinavian life science ventures
Creating a channel to make financing available for early-stage Scandinavian life science ventures, both seed capital and continued private and public venture funding.
Developing innovations into products
Network of medical technology research and development experts in various technical and medical fields that can assist the creativity and development of the therapies and tools.
Supporting with corporate functions
Supporting the ventures with shared resources in finance, business development, IT, marketing and administration allowing management to focus on product development.
Cardeon believes active ownership is core to a successful investment portfolio. To that end, Cardeon takes lead-investor roles with early-mid stage companies to directly contribute to their ongoing plans and activities, including:
Support
Strengthening the company with advisory assistance, board development, operational staff and advisors.
Product building
Converting early research into market identification and innovative commercial products.
Potential partners
Introducing potential collaboration partners.
Capitalization
Structuring the company for further external capitalization.
Markets
Assisting with access and advice on entry to international markets, particularly the U.S.
IPO
Advising on IPO approach and timing.
Cardeon normally wants a controlling ownership share and provide the company with initial working capital.
Setting the operational structure of the venture, optimizing it for medical technology development and further capitalization.
Cardeon intends to list the ventures at an early stage to broaden the shareholder base, raise funds and create liquidity for seed investors.
Trade
sale
The intention is normally to hand over the lead-investor role once product commercialization is about to commence.
Subscribe to our newsletter for current information about Cardeon AB.
© Cardeon AB 2022